Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

• Status: Terminated
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of dexamethasone intravitreal implant (Ozurdex) in combination with pars plana vitrectomy and membrane peeling for idiopathic epiretinal membrane (ERM).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Barnes Retina Institute
• Collaborator: Allergan
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Temazepam

Criteria

Inclusion Criteria:

• Patients with idiopathic epiretinal membrane

• Preoperative visual acuity of snellen equivalent 20/32 or worse

Exclusion Criteria:

• History or presence of any of the following:

• uveitis

• macular hole

• previous vitreoretinal surgery

• any other retinal pathology that could affect anatomic or functional results

• Age Related Macular Degeneration

• Diabetic Retinopathy

• Diabetic Macular Edema

• Retinal Vein Occlusion

• Pre-existing Macular Disease